Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests
UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?
You may also be interested in...
A major milestone has been reached in the EU after a cancer biomarker assay became the first product to receive a companion diagnostic certificate in the context of the EU In Vitro Diagnostic Regulation.
UK patient outcomes would improve under clearer, standardized market access or reimbursement pathways for advanced diagnostic tests, such as those used to screen for cancer, trade groups say.
The European Commission’s newly-launched Cancer Imaging Initiative will see sophisticated digital technologies based on artificial intelligence used to speed up medical innovations as part of its wider Beating Cancer Plan.